The Russian government will provide state subsidies for domestic drug exporters, in a move intended to raise the level of competitiveness of local drugs and their producers in the international arena, according to recent statements made by some senior state officials and local media reports.
It is planned that a significant part of these subsidies will be used for registration of Russian drugs in foreign markets.
The provision of subsidies has already been approved by Russia’s Prime Minister Mikhail Mishustin, according to whom the provision of subsidies will allow to reduce the cost of domestic drugs and stimulate a further growth of pharmaceutical exports from Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze